Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 22/04/2026 BST			5-day change	1st Jan Change
249.00 ^DKK	+0.77%		+1.16%	-23.44%

04-22	REPEAT & CORRECT : Amazon Launches Program for GLP-1 Weight-Loss Drugs Article on April 21	DJ
04-22	Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say	RE

Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN

Published on 07/04/2025 at 07:02 am BST

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

+0.77%

Jyske Bank has reduced its price target for Novo Nordisk to 700 Danish kroner from the previous 790, while maintaining its buy recommendation, according to Bloomberg News.

Latest news about Novo Nordisk A/S

04-22	REPEAT & CORRECT : Amazon Launches Program for GLP-1 Weight-Loss Drugs Article on April 21	DJ
04-22	Delay in Medicare pilot for obesity drugs may not hurt near-term demand, analysts say	RE
04-22	NOVO NORDISK : Deutsche Bank gives a Neutral rating	ZD
04-22	European health chief says EU is at 'a critical point' in ensuring new drug access	RE
04-22	Trump administration is indefinitely delaying a Medicare pilot program to cover weight-loss drugs - Axios	RE
04-22	European health chief says review of new weight-loss pill will conclude by summer	RE
04-22	Pfizer GLP-1 weight loss drug available for pre-order in China	RE
04-22	European health regulator chief says EU needs more say in securing access to new drugs	RE
04-22	ABB overtakes Novo Nordisk in market capitalization	FW
04-22	Nordic Equities in North America - Ericsson Slides 2.2 Percent	FW
04-22	PRESS DIGEST-Wall Street Journal - April 22	RE
04-22	Amazon.com Launches Program for GLP-1 Weight-Loss Drugs With One Medical -- Update	DJ
04-21	Health Care Up After UnitedHealth Earnings -- Health Care Roundup	DJ
04-21	Amazon.com to Offer Program for GLP-1 Weight-Loss Drugs	DJ
04-21	UnitedHealth flags challenges in Medicare obesity drug pilot	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

05-06 - Earnings release - Q1 2026

More about the company